Microimaging ultrasound developer VisualSonics of Toronto said that it is licensing a contrast agent for the quantification of myocardial perfusion in preclinical studies from the University of Virginia in Charlottesville, VA.
The contrast agent will be sold under the trademark Depo, VisualSonics said.
In addition to licensing Depo, the company said it is establishing molecular protocols for contrast kits to be used for preclinical imaging across multiple application areas, such as developing a targeted contrast agent for quantification of angiogenesis using VEGFR2 as a marker and P-selectin as a marker for inflammation.
By AuntMinnie.com staff writers
January 26, 2006
Copyright © 2006 AuntMinnie.com
